Adults taking Eli Lilly's Zepbound lost 47% more weight on average than those on Novo Nordisk's Wegovy, Lilly ...
Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
Eli Lilly said it would invest $3 billion to expand a recently ... a study that claimed that its Zepbound obesity drug is ...